Regulus Therapeutics Inc. (NASDAQ:RGLS) shares traded up 3.9% during trading on Monday . The company traded as high as $3.83 and last traded at $3.71, with a volume of 304,496 shares traded. The stock had previously closed at $3.57.

Several brokerages have recently issued reports on RGLS. FBR & Co reiterated a “buy” rating and issued a $30.00 price objective on shares of Regulus Therapeutics in a research note on Sunday, April 17th. Wells Fargo & Co. began coverage on Regulus Therapeutics in a research note on Tuesday, May 3rd. They issued a “buy” rating on the stock. BMO Capital Markets cut Regulus Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $16.00 to $4.00 in a research note on Tuesday, June 28th. Wedbush reiterated an “outperform” rating and issued a $15.00 price objective on shares of Regulus Therapeutics in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Regulus Therapeutics in a research note on Tuesday, May 3rd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Regulus Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $10.17.

The company’s 50-day moving average is $3.99 and its 200-day moving average is $5.77. The firm’s market cap is $186.32 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.02. On average, equities research analysts expect that Regulus Therapeutics Inc. will post ($1.54) EPS for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.